DiNAQOR is a life sciences company builder focused on launching innovative firms in tissue science, precision, and genetic medicine. The platform provides seamless access to GMP manufacturing capabilities for developing advanced medical solutions. This structure supports the creation and scaling of next-generation therapeutic technologies.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene therapy delivery methods often lack organ specificity, leading to off-target effects and reduced therapeutic efficacy, particularly in treating heart diseases. This lack of targeted delivery limits the potential of gene therapies to address the high unmet medical needs in patients with heart conditions.
Solution
DiNAQOR is developing a gene therapy platform that leverages proprietary human-based tissue drug development to enable organ-specific delivery of gene therapies, focusing initially on heart disease. Their approach aims to improve treatment efficacy by delivering therapeutic solutions directly to the affected organ, minimizing systemic exposure and maximizing the therapeutic impact. The company is also scaling and commercializing DiNAMIQS, a development and manufacturing platform for cell and gene therapies.
Target Audience
The primary target audience includes patients with heart disease who could benefit from targeted gene therapies, as well as pharmaceutical companies and research institutions involved in gene therapy development.
Features
- Organ-specific gene therapy delivery platform
- Proprietary human-based tissue drug development process
- Targeted therapeutic solutions for heart disease
- DiNAMIQS: A development and manufacturing platform for cell and gene therapies